No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases
Mahmoud, Remi; Dutch Initiative on Crohn and Colitis (ICC)
(2019) Gastroenterology, volume 156, issue 5, pp. 1333 - 1344.e3
(Article)
Abstract
Background & Aims: Patients with inflammatory bowel diseases who have postinflammatory polyps (PIPs) have an increased risk of colorectal neoplasia (CRN). European guidelines propose that patients with PIPs receive more frequent surveillance colonoscopies, despite limited evidence of this increased risk. We aimed to define the risk of CRN and colectomy
... read more
in patients with inflammatory bowel diseases and PIPs. Methods: We conducted a multicenter retrospective cohort study of patients with inflammatory bowel diseases who underwent colonoscopic surveillance for CRN, from January 1997 through January 2017, at 5 academic hospitals and 2 large nonacademic hospitals in New York or the Netherlands. Eligible patients had confirmed colonic disease with duration of at least 8 years (or any duration, if they also had primary sclerosing cholangitis) and no history of advanced CRN (high-grade dysplasia or colorectal cancer) or colectomy. The primary outcome was occurrence of advanced CRN according to PIP status; secondary outcomes were occurrence of CRN (inclusive of low-grade dysplasia) and colectomy. Results: Of 1582 eligible patients, 462 (29.2%) had PIPs. PIPs were associated with more severe inflammation (adjusted odds ratio 1.32; 95% confidence interval [CI] 1.13–1.55), greater disease extent (adjusted odds ratio 1.92; 95% CI 1.34–2.74), and lower likelihood of primary sclerosing cholangitis (adjusted odds ratio 0.38; 95% CI 0.26–0.55). During a median follow-up period of 4.8 years, the time until development of advanced CRN did not differ significantly between patients with and those without PIPs. PIPs did not independently increase the risk of advanced CRN (adjusted hazard ratio 1.17; 95% CI 0.59–2.31). The colectomy rate was significantly higher in patients with PIPs (P =.01). Conclusions: In a retrospective analysis of data from 2 large independent surveillance cohorts, PIPs were associated with greater severity and extent of colon inflammation and higher rates of colectomy, but were not associated with development of any degree of CRN. Therefore, intervals for surveillance should not be shortened based solely on the presence of PIPs.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Crohn Colitis, Crohn Disease, Primary Sclerosing Cholangitis, Ulcerative Colitis, Colorectal Neoplasms/epidemiology, Crohn Disease/epidemiology, Prevalence, Humans, Middle Aged, Male, Colectomy, New York City/epidemiology, Colonic Polyps/epidemiology, Neoplasm Grading, Time Factors, Colonoscopy, Adult, Female, Retrospective Studies, Netherlands/epidemiology, Colitis, Ulcerative/epidemiology, Risk Assessment, Risk Factors, Early Detection of Cancer/methods, Biopsy, Gastroenterology, Hepatology, Journal Article, Multicenter Study
ISSN: 0016-5085
Publisher: W.B. Saunders Ltd
Note: Funding Information: Conflicts of interest Remi Mahmoud, Shailja C. Shah, Joren R. ten Hove, Erik Mooiweer, Daniel Castaneda, Jason Glass, Jordan Elman, Akash Kumar, Jordan Axelrad, and Steven H. Itzkowitz have no disclosures. Joana Torres has served as a consultant for Takeda and received speaker fees from Takeda, AbbVie, and Ferring. Thomas Ullman has served as consultant for Salix/Valeant and for Janssen. Jean-Frederic Colombel has served as consultant, advisory board member, or speaker for AbbVie, Amgen, Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Lilly, Medimmune, Merck & Co, Pfizer, PPM Services, Protagonist, Second Genome, Seres, Shire, Takeda, Theradiag, and Theravance Biopharma; has stock options in Intestinal Biotech Development, and Genfit; and has received research grants from AbbVie, Takeda, and Janssen and Janssen. Bas Oldenburg has served as consultant for MSD, Takeda, AbbVie, Ferring, Cablon, and Janssen; received unrestricted grants from AbbVie, Ferring, Dr Falk, MSD, Takeda, and Janssen; and received speakers’ fees from Ferring and MSD. Publisher Copyright: © 2019 AGA Institute Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
(Peer reviewed)